Aspirin IV Market Summary

Key Factors Driving Aspirin IV Growth

1. Large unmet need for a rapidly deliverable aspirin formulation: Aspirin is a well-established antiplatelet and anti-inflammatory drug used in cardiovascular disease, acute ischemic stroke and other conditions. Rhoshan's IV formulation is designed to provide aspirin directly into the bloodstream, which could be valuable when patients cannot swallow or absorb oral medication or when rapid platelet inhibition is desired. The company is developing a 325-mg rapid-IV-push formulation, with its Phase I program directly comparing IV aspirin with oral aspirin.

2. Potential opportunity in Kawasaki disease: Rhoshan's Aspirin for Injection received FDA orphan-drug designation in September 2020 for Kawasaki disease. Kawasaki disease is generally treated with aspirin as part of standard therapy, but critically ill children may have difficulty receiving oral medication. An injectable formulation could therefore address an important administration gap. The orphan designation provides regulatory incentives, although it does not represent approval or demonstrated commercial success.

3. Strong underlying clinical importance of aspirin in cardiovascular and cerebrovascular care: Aspirin's established antiplatelet activity provides a substantial scientific and clinical foundation for the IV product. Aspirin irreversibly inhibits platelet cyclooxygenase, reducing thromboxane-mediated platelet aggregation. Early aspirin administration is an established component of acute ischemic-stroke management in appropriate patients, although IV aspirin should not be assumed to replace oral aspirin or be used immediately after thrombolysis. The ARTIS randomized trial, for example, found that giving 300 mg IV aspirin within 90 minutes of alteplase did not improve 3-month outcomes and increased symptomatic intracranial hemorrhage.

4. Growing interest in IV aspirin during neurointerventional procedures: One of the more promising potential niches is mechanical thrombectomy/carotid stenting for acute ischemic stroke. Published observational data have examined IV aspirin during acute carotid stenting, including a multicenter dataset in which 70 of 1,557 patients (4.5%) underwent tandem-occlusion treatment with acute carotid stenting plus a 250-mg IV aspirin bolus. The study found comparable rates of symptomatic intracranial hemorrhage and 90-day mortality versus matched controls, supporting continued investigation of IV aspirin in this procedural setting.

5. Proprietary formulation technology may differentiate the product: Rhoshan has developed patented technology intended to address aspirin's aqueous instability and enable a stable injectable formulation. Its patents describe a lyophilized crystalline aspirin formulation and a two-vial system containing aspirin plus a diluent/basifying agent. The company received a U.S. patent for improved stable aspirin formulations for IV use in July 2024, providing intellectual-property protection around the formulation approach.

Aspirin IV Recent Developments

In September 2025, Aspire Biopharma Holdings announced positive final results from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults.

“Aspirin IV Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Aspirin IV for potential indication like Coronary disorders in the 7MM. A detailed picture of Aspirin IV’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Aspirin IV for potential indications. The Aspirin IV market report provides insights about Aspirin IV’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Aspirin IV performance, future market assessments inclusive of the Aspirin IV market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Aspirin IV sales forecasts, along with factors driving its market.

Aspirin IV Drug Summary

Aspirin IV is an intravenous formulation of acetylsalicylic acid (aspirin) designed to provide rapid and reliable antiplatelet activity in acute cardiovascular emergencies, particularly acute coronary syndrome (ACS) and acute myocardial infarction (AMI), where early platelet inhibition is critical. Aspirin irreversibly inhibits cyclooxygenase enzymes, particularly COX-1 in platelets, thereby suppressing thromboxane A2 production and reducing platelet aggregation and thrombus formation. Unlike conventional oral aspirin, the intravenous route is intended to provide a faster onset of antiplatelet activity and more predictable drug exposure, while also enabling administration to patients who are unable to swallow, are nauseated, or are unconscious. Commercial intravenous formulations may contain a soluble acetylsalicylate salt, such as lysine acetylsalicylate, supplied as a powder for reconstitution and subsequent intravenous administration. Aspirin IV is being further developed in reformulated versions, including Hyloris Pharmaceuticals' product, for use in emergency cardiovascular settings, with the company reporting successful completion of a pivotal study and a planned U.S. regulatory submission in 2026. The report provides Aspirin IV’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Aspirin IV Market Report

The report provides insights into:

• A comprehensive product overview including the Aspirin IV MoA, description, dosage and administration, research and development activities in potential indication like Coronary disorders.
• Elaborated details on Aspirin IV regulatory milestones and other development activities have been provided in Aspirin IV market report.
• The report also highlights Aspirin IV‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Aspirin IV market report also covers the patents information, generic entry and impact on cost cut.
• The Aspirin IV market report contains current and forecasted Aspirin IV sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Aspirin IV market report also features the SWOT analysis with analyst views for Aspirin IV in potential indications.

Methodology

The Aspirin IV market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Aspirin IV Analytical Perspective by DelveInsight

• In-depth Aspirin IV Market Assessment

This Aspirin IV sales market forecast report provides a detailed market assessment of Aspirin IV for potential indication like Coronary disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Aspirin IV sales data uptil 2034.

• Aspirin IV Clinical Assessment

The Aspirin IV market report provides the clinical trials information of Aspirin IV for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Aspirin IV Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Aspirin IV Market Potential & Revenue Forecast

• Projected market size for the Aspirin IV and its key indications
• Estimated Aspirin IV sales potential (Aspirin IV peak sales forecasts)
• Aspirin IV Pricing strategies and reimbursement landscape

Aspirin IV Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Aspirin IV Market positioning compared to existing treatments
• Aspirin IV Strengths & weaknesses relative to competitors

Aspirin IV Regulatory & Commercial Milestones

• Aspirin IV Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Aspirin IV Clinical Differentiation

• Aspirin IV Efficacy & safety advantages over existing drugs
• Aspirin IV Unique selling points

Aspirin IV Market Report Highlights

• In the coming years, the Aspirin IV market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Aspirin IV companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Aspirin IV’s dominance.
• Other emerging products for Coronary disorders are expected to give tough market competition to Aspirin IV and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Aspirin IV in potential indications.
• Analyse Aspirin IV cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Aspirin IV sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Aspirin IV in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Aspirin IV? How strong is Aspirin IV’s clinical and commercial performance?
• What is Aspirin IV’s clinical trial status in each individual indications such as Coronary disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Aspirin IV Manufacturers?
• What are the key designations that have been granted to Aspirin IV for potential indications? How are they going to impact Aspirin IV’s penetration in various geographies?
• What is the current and forecasted Aspirin IV market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Aspirin IV in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Aspirin IV for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Aspirin IV? What is the duration of therapy and what are the geographical variations in cost per patient?